We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -27.00 | -1.49% | 1,785.50 | 1,785.50 | 1,786.00 | 1,802.00 | 1,785.00 | 1,792.50 | 713,598 | 12:17:02 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.97 | 73.78B |
From May 2019 to May 2024
By Ian Walker
GlaxoSmithKline PLC's (GSK.LN) joint-venture company ViiV Healthcare said Thursday that a global phase 3 "Atlas-2M" study of rilpivirine for the treatment of HIV met its primary endpoint.
ViiV Healthcare--which is jointly owned by Pfizer Inc. (PFE)--said the study showed a combination of cabotegravir and rilpivirine administered every eight weeks is similar to a four-week administration.
"The Atlas-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year," Viiv Healthcare's Head of Research & Development Kimberly Smith said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 22, 2019 02:55 ET (06:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
